Check out your Company Bowl for anonymous work chats.
As 2025 comes to a close, we want to pause and express our deep gratitude for our customers, partners and employees. We're energized by the opportunities ahead to create meaningful impact in healthcare together. Merry Christmas and happy holidays! Wishing you a joyful season filled with peace, happiness, and success in the coming year. Please note that our offices will be closed starting December 24 through January 1. We’ll see you at the start of 2026 🎊
While healthcare is rapidly accelerating the development of LLM-based health agents, the industry still lacks a standardized way to measure how effectively these models retrieve and reason over actual FHIR data. In collaboration with the Massachusetts Institute of Technology and Korea Advanced Institute of Science and Technology, Verily created FHIR-AgentBench — a rigorous, open-source framework to evaluate how AI retrieves and reasons over complex patient records — establishing a new standard for building safer, more reliable health AI systems. The Result? We moved the needle, increasing accuracy from 50% to 80% on complex clinical question-answering tasks. We’re open-sourcing the benchmark to help the industry build more reliable, high-fidelity AI systems for precision health. Read the full technical deep-dive from Verily Senior Data Scientist Jong Ha L. and Data Scientist Eléa Bach.
It’s not enough to simply detect pathogens in wastewater; public health leaders need to understand how they move to make informed decisions. Our partner team at Bangor University is utilizing advanced models to simulate how viruses disperse from rivers to coastal waters. This data creates spatial risk maps, helping governments visualize contamination zones and anticipate outbreaks, even during extreme weather events. Verily is translating these models into clearer, smarter risk assessments for public health: https://viraqua.uk/en/our-science/models
We are thrilled to announce that in collaboration with the Broad Institute of MIT and Harvard, DataTecnica, Northwestern University Feinberg School of Medicine, Sage Bionetworks, Technome, and Vanderbilt University Medical Center, Verily has secured a two-year renewal for the NIH System Biology (SysBio) award. This $9.2 million in continued funding will further the development and implementation of the FAIRplex platform, empowering researchers to efficiently find, access, and analyze data from Accelerating Medicines Partnership® (AMP®) projects and beyond. The platform will help foster a deeper understanding of the systems biology underpinning human health and disease. "This renewed funding underscores the critical importance of creating a unified, accessible, and secure data ecosystem as researchers look to apply advanced AI and machine learning techniques to accelerate scientific findings," says Andrew Trister, MD, PhD, Chief Medical and Scientific Officer at Verily.
Advanced wastewater monitoring empowers public health officials with insights for rapid and targeted disease response. Watch our on-demand webinar to hear real-world success stories from public health experts in Hawaii and Texas, who leveraged wastewater monitoring in their H5N1 responses.
Andrew Trister, our Chief Medical and Scientific Officer, reflected on 2025 innovations at Verily, highlighting the launches of Verily Pre, our precision health platform, and Verily Me, our consumer health app. Both efforts align with the growing focus on using health data to drive personalized, actionable insights.
Data from the Centers for Disease Control and Prevention shows a rise in positive norovirus cases across the country. Wastewater surveillance offers the most real-time view of what's circulating in a community for diseases like flu, RSV, COVID-19, and norovirus. Verily is working on the front lines of this effort, including at a treatment site in Indiana, where there has been a spike in cases. Read more and how to stay safe during the holidays.
GLP-1s have transformed cardiometabolic care, yet major blind spots remain because traditional health data shows what happens, but not always why. Verily Viewpoint Evidence is helping close critical data gaps through an ongoing, real-world view of health, enabling researchers to uncover drivers of disease, treatment response, and wellbeing. From revealing the mechanisms of GLP-1s for cardiometabolic care to exploring other pharmacologic potential, Verily is advancing precision evidence for research, and setting a new standard for real-world understanding.
Fragmented data hinders biopharma R&D. Learn how a trusted research environment (TRE) can unify your complex healthcare data.
"As we look to the idea of an 'AI doctor' to help fill care gaps, we can take lessons from the path of self-driving cars, and Waymo. Technology alone is not going to get us there. We will need alignment and coordination with regulatory agencies, clinicians, and the current healthcare system to make progress." Stephen Gillett, Verily CEO, spoke with Alec C. Kimmelman, MD, PhD of NYU Langone Health, Trent Norris of NVIDIA and moderator Katharine Schwab about improving the patient experience at the Forbes Healthcare Summit today, noting our new consumer health app, Verily Me: "Health search is quickly dropping off. People are turning to LLMs. We launched Verily Me, which allows you to get personalized care recommendations from clinicians. With our AI companion called Violet, you can have a conversation about your labs and medical records from across your providers, as you go through your care journey. We are committed to bringing precision health to patients everywhere, every day. That's what we're trying to do with Verily Me."
